116 related articles for article (PubMed ID: 22162184)
1. Placebo effect characteristics observed in a single, international, longitudinal study in Huntington's disease.
Cubo E; González M; del Puerto I; de Yébenes JG; Arconada OF; Gabriel y Galán JM;
Mov Disord; 2012 Mar; 27(3):439-42. PubMed ID: 22162184
[TBL] [Abstract][Full Text] [Related]
2. Riluzole in Huntington's disease: a 3-year, randomized controlled study.
Landwehrmeyer GB; Dubois B; de Yébenes JG; Kremer B; Gaus W; Kraus PH; Przuntek H; Dib M; Doble A; Fischer W; Ludolph AC;
Ann Neurol; 2007 Sep; 62(3):262-72. PubMed ID: 17702031
[TBL] [Abstract][Full Text] [Related]
3. Factors contributing to institutionalization in patients with Huntington's disease.
Rosenblatt A; Kumar BV; Margolis RL; Welsh CS; Ross CA
Mov Disord; 2011 Aug; 26(9):1711-6. PubMed ID: 21538527
[TBL] [Abstract][Full Text] [Related]
4. A controlled trial of idebenone in Huntington's disease.
Ranen NG; Peyser CE; Coyle JT; Bylsma FW; Sherr M; Day L; Folstein MF; Brandt J; Ross CA; Folstein SE
Mov Disord; 1996 Sep; 11(5):549-54. PubMed ID: 8866496
[TBL] [Abstract][Full Text] [Related]
5. Assessment of involuntary choreatic movements in Huntington's disease--toward objective and quantitative measures.
Reilmann R; Bohlen S; Kirsten F; Ringelstein EB; Lange HW
Mov Disord; 2011 Oct; 26(12):2267-73. PubMed ID: 21661053
[TBL] [Abstract][Full Text] [Related]
6. The unified Huntington's Disease Rating Scale for advanced patients: validation and follow-up study.
Youssov K; Dolbeau G; Maison P; Boissé MF; Cleret de Langavant L; Roos RA; Bachoud-Lévi AC
Mov Disord; 2013 Dec; 28(14):1995-2001. PubMed ID: 24123464
[TBL] [Abstract][Full Text] [Related]
7. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.
Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
J Clin Psychiatry; 2011 Apr; 72(4):464-72. PubMed ID: 21527123
[TBL] [Abstract][Full Text] [Related]
8. Effect of fetal neural transplants in patients with Huntington's disease 6 years after surgery: a long-term follow-up study.
Bachoud-Lévi AC; Gaura V; Brugières P; Lefaucheur JP; Boissé MF; Maison P; Baudic S; Ribeiro MJ; Bourdet C; Remy P; Cesaro P; Hantraye P; Peschanski M
Lancet Neurol; 2006 Apr; 5(4):303-9. PubMed ID: 16545746
[TBL] [Abstract][Full Text] [Related]
9. A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington's disease.
Huntington Study Group HART Investigators
Mov Disord; 2013 Sep; 28(10):1407-15. PubMed ID: 23450660
[TBL] [Abstract][Full Text] [Related]
10. A pilot study using nabilone for symptomatic treatment in Huntington's disease.
Curtis A; Mitchell I; Patel S; Ives N; Rickards H
Mov Disord; 2009 Nov; 24(15):2254-9. PubMed ID: 19845035
[TBL] [Abstract][Full Text] [Related]
11. [The effect of piracetam on involuntary movements in Huntington's disease. A double-blind, placebo-controlled study].
Mateo D; Giménez-Roldán S
Neurologia; 1996 Jan; 11(1):16-9. PubMed ID: 8714171
[TBL] [Abstract][Full Text] [Related]
12. Unified Huntington's disease rating scale: a follow up.
Siesling S; van Vugt JP; Zwinderman KA; Kieburtz K; Roos RA
Mov Disord; 1998 Nov; 13(6):915-9. PubMed ID: 9827615
[TBL] [Abstract][Full Text] [Related]
13. A controlled trial of fluoxetine in nondepressed patients with Huntington's disease.
Como PG; Rubin AJ; O'Brien CF; Lawler K; Hickey C; Rubin AE; Henderson R; McDermott MP; McDermott M; Steinberg K; Shoulson I
Mov Disord; 1997 May; 12(3):397-401. PubMed ID: 9159735
[TBL] [Abstract][Full Text] [Related]
14. A randomized, placebo-controlled trial of AFQ056 for the treatment of chorea in Huntington's disease.
Reilmann R; Rouzade-Dominguez ML; Saft C; Süssmuth SD; Priller J; Rosser A; Rickards H; Schöls L; Pezous N; Gasparini F; Johns D; Landwehrmeyer GB; Gomez-Mancilla B
Mov Disord; 2015 Mar; 30(3):427-31. PubMed ID: 25689146
[TBL] [Abstract][Full Text] [Related]
15. The relationship between CAG repeat length and clinical progression in Huntington's disease.
Ravina B; Romer M; Constantinescu R; Biglan K; Brocht A; Kieburtz K; Shoulson I; McDermott MP
Mov Disord; 2008 Jul; 23(9):1223-7. PubMed ID: 18512767
[TBL] [Abstract][Full Text] [Related]
16. The long-term effect of tetrabenazine in the management of Huntington disease.
Fasano A; Cadeddu F; Guidubaldi A; Piano C; Soleti F; Zinzi P; Bentivoglio AR
Clin Neuropharmacol; 2008; 31(6):313-8. PubMed ID: 19050408
[TBL] [Abstract][Full Text] [Related]
17. Health-related quality of life in Huntington's disease: Which factors matter most?
Ho AK; Gilbert AS; Mason SL; Goodman AO; Barker RA
Mov Disord; 2009 Mar; 24(4):574-8. PubMed ID: 19097181
[TBL] [Abstract][Full Text] [Related]
18. Unified Huntington's Disease Rating Scale: reliability and consistency. Huntington Study Group.
Mov Disord; 1996 Mar; 11(2):136-42. PubMed ID: 8684382
[TBL] [Abstract][Full Text] [Related]
19. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
[TBL] [Abstract][Full Text] [Related]
20. Impact of placebo assignment in clinical trials of tic disorders.
Cubo E; González M; Singer H; Mahone EM; Scahill L; Müller-Vahl KR; de la Fuente-Fernández R; Armesto D; Kompoliti K
Mov Disord; 2013 Aug; 28(9):1288-92. PubMed ID: 23408491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
